ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0326

Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)

Maha Almackenzie1, Anushka Aggarwal2, shiri keret3, shreya Sriram4, Tanya Chandra5, Raisa Silva6, Eugenia Gkiaouraki4, Siamak Mogahadam7, Chester Oddis7 and Rohit Aggarwal8, 1Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, 2Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, 3Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5University of Pittsburgh Medical Center, Pittsburgh, PA, 6Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

Meeting: ACR Convergence 2024

Keywords: Muscle Biology, Myositis, SF36

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: There are six core set measures (CSMs) of disease activity in patients with idiopathic inflammatory myopathies (IIM). However, there is limited data on their clinical association, meaningfulness (validity) and improvement thresholds (responsiveness) using quality of life measures in myositis. The 36-Item Short Form Health Survey (SF-36) assesses quality of life, functional health, and well-being. This study evaluates the association and improvement thresholds of various CSMs using SF-36 in patients with IIM.

Methods: Adults with IIM enrolled in two clinical trials (AttackmyILD, Tocilizumab in Myositis) and one observational study (PAMPRO) were evaluated for the study. Data on demographics (Table 1) and CSMs including patient-global assessment (PtGD), physician-global assessment (PhGD), extra global disease activity score (EXGLB), manual muscle testing (MMT), HAQ, creatine kinase (CPK), and SF-36 were collected at baseline, 12 weeks, and 24 weeks in all three studies. Spearman’s correlation assessed associations between SF-36 domains (physical functioning, social functioning, emotional well-being, emotional problems, general mental health, energy/fatigue, bodily pain, general health) and summary scores for physical health (PCS) and mental health (MCS) with CSMs. A mixed-effect linear model identified CSM predictors for SF-36 domains. Minimal Clinically Important Difference (MCID) was determined using a 7.2 score improvement in PCS as an anchor.

Results: The study included 150 IIM patients (63.8% female, 84.8% white, mean age 52 ± 13.6 years): 44.2% with dermatomyositis, 29.8% with anti-synthetase syndrome, 18.3% with polymyositis, and 7.7% with necrotizing myopathy.

Spearman correlation showed strong to moderate negative correlations of PtGD and HAQ with nearly all SF-36 domains, moderate negative correlations for PhGD, and weak negative correlations for EXGLB. MMT and CPK were not significant (Table 2). The linear-effect model identified HAQ as a strong predictor for all SF-36 domains (P < 0.05) except emotional well-being. PtGD predicted bodily pain, physical functioning, social functioning, energy/fatigue, and PCS (P < 0.001). CPK predicted bodily pain, social functioning, energy/fatigue, emotional problems, and MCS (P < 0.05). EXGLB was significant for energy/fatigue only (P = 0.01).

Using a 7.2 PCS improvement as an anchor, CSM improvements aligned with observed PCS improvements except for CPK. MCID was calculated for each of the CSMs (Table 3).

Conclusion: Most CSMs in IIM is significantly associated with multiple congruent domains and summary score of SF-36 except for the MMT and CPK. CSMs strongly predicted relevant domains and summary score of SF-36. All CSMs improved with SF-36 PCS improvement except CPK, and MCIDs were determined.

Supporting image 1

Table 1: Patient characteristics and baseline SF_36 domains mean ± SD.

Supporting image 2

Table 2: Spearman correlation analysis between the SF_36 domains and core set measures at baseline.

Supporting image 3

Table 3: Core set measures mean at baseline, mean change by PCS improvement vs. no improvement at 24 weeks, P-value for the mean change and MCID for CSMs.


Disclosures: M. Almackenzie: None; A. Aggarwal: None; s. keret: None; s. Sriram: None; T. Chandra: None; R. Silva: None; E. Gkiaouraki: None; S. Mogahadam: None; C. Oddis: Abcuro, 5, Alexion, 5, Argenx, 5, Boehringer Ingelheim, 5, CSL Behring, 5, EMD Serono, 5, Janssen, 5, Pfizer, 5, Priovant, 5; R. Aggarwal: Alexion, 2, ANI Pharmaceuticals, 2, Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, CabalettaBio, 2, Capella Bioscience, 2, Capstanx, 2, Corbus, 2, CSL Behring, 2, EMD Serono, 2, 5, Galapagos, 2, Horizon Therapeutics, 2, I-Cell, 2, Immunovant, 2, Janssen, 1, 2, 5, Kezar, 2, Kyverna, 2, Lilly, 2, Mallinckrodt, 5, Manta Medicines Corporation, 2, Merck, 2, Novartis, 2, Nuvig Therapeutics, 2, Octapharma, 2, Pfizer, 2, 5, Q32, 5, Roivant, 2, Sanofi, 2, Teva, 2.

To cite this abstract in AMA style:

Almackenzie M, Aggarwal A, keret s, Sriram s, Chandra T, Silva R, Gkiaouraki E, Mogahadam S, Oddis C, Aggarwal R. Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/validity-and-responsiveness-of-core-set-measures-in-idiopathic-inflammatory-myositis-based-on-36-item-short-form-health-survey-sf-36/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-and-responsiveness-of-core-set-measures-in-idiopathic-inflammatory-myositis-based-on-36-item-short-form-health-survey-sf-36/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology